We collaborate with leading biopharmaceutical and technology companies to broadly explore diverse disease domains and rapidly identify novel therapeutic candidates.

Interested in partnering with Recursion? Connect with us at partner@recursion.com.

The Bayer - Recursion Oncology Collaboration

The Neuroscience and GI Oncology Collaboration with Roche and Genetech

The Most Powerful Supercomputer in Pharma

Therapeutic partners

Technology, data, and capability partners

The goal of every partnership is to create therapeutics, yet the approach may take multiple forms:

Strategic
collaboration

In order to achieve our mission, we partner with leading biotechnology companies, pharmaceutical companies and academic research institutions to identify novel therapeutics and unlock biological insights using our discovery technology. Our partnering efforts take two primary forms: discovery platform partnerships and asset development partnerships.

Asset Development Partnership

In addition to NCEs, the Recursion Map may discover new uses for known chemical entities owned or controlled by third parties. In such circumstances, we may in-license rights to these assets to advance these programs internally.

Discovery Platform Partnerships

We have collaborated with third parties to broadly explore diverse disease domains (e.g., fibrosis, neuroscience, and oncology). Collaborations leverage our partner's deep domain expertise and Recursion's unique capability to map and navigate complex biology to identify and rapidly advance potential therapeutics.

“We are delighted to collaborate with Recursion’s world-class team, which is doing pioneering work in digital biology and chemistry with NVIDIA DGX and NVIDIA AI software to accelerate the development of the world’s largest biomolecular generative AI models and speed drug discovery for biotech and pharmaceutical companies.”

Jensen Huang
Founder and CEO of NVIDIA

“The collaboration with Recursion enables us to discover small molecule drug candidates targeting novel biology for the treatment of fibrotic diseases and complements our expertise in cardiovascular research with digital technologies.”

Joerg Moeller, MD
Member of the Executive Committee of Bayer AG's Pharmaceuticals Division and Head of Research and Development

"This collaboration highlights the potential of technology to transform drug discovery and unlock previously unknown insights into complex disease in an unbiased way."

James Sabry, MD, PhD
Global Head of Pharma Partnering at Roche

Interested in partnering with us?

Contact us
© 2025 Recursion. All rights reserved.